2026-11-092026-11-09https://scholars.csmu.edu.tw/handle/123456789/38792The incidence of asthma has increased substantially in the last two decades. New medication is developed rapidly in recent years to apply to allergic asthma, since lots of people have investigated about these. However, now existing drugs just offer partial relief of symptoms in such disease. The goal of feature is to understand the complicated mechanism of asthma, and develop more effective drugs for suppressing the inflammatory response in asthma. Even we can then reverse the damaged lung tissue after airway remodeling. As we known today, asthma is a repeated chronic inflammatory disease. It is characterized by a complex response of pulmonary eosinophilia, edema, mucus hypersecretion, and airway hyperreactivity. Under the condition of long term asthma, airway remodeling may develop by increased goblet cells, subepithelial fibrosis, airway smooth muscle mass increased and vascular hyperplasia. These make asthma control more difficult. According to recent research about asthma, leukotriene got important role in whole pathologic change of asthma. Other studies also found the immunomodulatory activity of some purified Chinese herbs and foods in suppressing airway remodeling. We would examine the role of leukotriene receptor antagonist and agent of edible golden needle mushroom extract─FIP (fungal immunomodulatory peptide) –fve in a mouse asthma model after allergen-induced chronic lung inflammation and airway remodeling. Female BALB/c mice, after intraperitoneal ovalbumin sensitization on Days 0 and 14, received intranasal OVA on Days14 and Days 25-27. The mouse asthma model was set up. Airway remodeling model was then set up following by intranasal OVA on Days 46, 60, 69, 71 and 73. The sensitized mice were divided into different group according to the course of designed airway change. Different groups of sensitized mice received Montelukast (leukotriene receptor antagonist) or FIP-fve via intragastric feeding on Day 15-27. The other groups of sensitized mice received same drugs as above mention or combination of FIP-fve on Day 74-104. In this experiment, we will evaluate the efficacy of Montelukast and FIP-fve on asthma treatment. We will also evaluate the effect of drugs on reversing the established remodeling airway to normal airway tissue.在中國人及日本人的日常飲食中金針菇是一種常見的食品。近年來更有研究顯示金 針菇萃取物藉由增強免疫細胞中的細胞激素如IL-2 與IFN-g 被當成有抗腫瘤與抗病毒 的作用。 過去二十年間，氣喘疾病的發生率持續快速增加中。現今已知的觀念，氣喘是一種 複雜反覆慢性發炎的疾病，病理上的變化包括有肺部嗜伊紅性白血球的浸潤,水腫,黏液 的過度分泌以及呼吸道的過度反應。而在長期氣喘的狀態下，呼吸道會產生杯狀細胞、 上皮下纖維、平滑肌肉組織、血管等增生的呼吸道重塑現象，因而增加控制氣喘的困難 度。其中主要被認同的機轉是免疫調控不平衡所致。隨著越來越多人投入氣喘的研究， 治療過敏氣喘的新藥劑不斷被開發出來。但目前已知的藥物僅能提供疾病症狀的部分舒 解。如何回復已損傷重塑過的肺組織仍是未來努力的目標。 我們將藉由金針菇萃取物的增強細胞激素的功效來逆轉免疫調控不平衡的動物氣 喘模式再加上白三烯素及其受體的拮抗劑而達到預防及治療的目的。如果有療效實為氣 喘患者的福音。 因此第一年我們將觀察白三烯素受體的拮抗劑，以及金針菇萃取物在急性期的預防 及治療角色。致敏的老鼠，依照實驗時程分組的不同，分別於氣喘模組建立過程的第0 天到第13 天給予金針菇萃取物，第15 天至第27 天則再加餵食針餵食白三烯素受體拮 抗劑，或是在第15 天至第27 天直接餵食白三烯素受體拮抗劑與金針菇萃取物。第二年 則於氣道重塑模組建立過程的第74 天至第104 天，餵食白三烯素受體拮抗劑及金針菇 萃取物。第三年則將前述療程合併由預防(早期的第0 天到第13 天給予藥物)到治療(晚 期的第15 天到第27 天給予藥物)及氣道重塑模組建立過程的第74 天至第104 天的效 果。藉由上述實驗，我們將確定在老鼠的氣喘模組中三烯素受體拮抗劑及金針菇萃取 物，是否有治療的效果，甚至老鼠在長期氣喘已發生氣道重塑的模組中，是否有回復正 常組織的功效。Project